[go: up one dir, main page]

CL2017000293A1 - Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) - Google Patents

Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)

Info

Publication number
CL2017000293A1
CL2017000293A1 CL2017000293A CL2017000293A CL2017000293A1 CL 2017000293 A1 CL2017000293 A1 CL 2017000293A1 CL 2017000293 A CL2017000293 A CL 2017000293A CL 2017000293 A CL2017000293 A CL 2017000293A CL 2017000293 A1 CL2017000293 A1 CL 2017000293A1
Authority
CL
Chile
Prior art keywords
divisional
hepatitis
compounds derived
treatment
pharmaceutical composition
Prior art date
Application number
CL2017000293A
Other languages
English (en)
Inventor
Pek Yoke Chong
John F Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000293(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2017000293A1 publication Critical patent/CL2017000293A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>COMPUESTOS DERIVADOS DE BENZOFURANO; Y PROCESO PARA PREPARAR COMPUESTOS DERIVADOS DE BENZOFURANO (DIVISIONAL SOL. N° 393-2014)</p>
CL2017000293A 2011-08-19 2017-02-03 Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) CL2017000293A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23

Publications (1)

Publication Number Publication Date
CL2017000293A1 true CL2017000293A1 (es) 2017-10-06

Family

ID=47746761

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014000393A CL2014000393A1 (es) 2011-08-19 2014-02-17 Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
CL2017000293A CL2017000293A1 (es) 2011-08-19 2017-02-03 Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014000393A CL2014000393A1 (es) 2011-08-19 2014-02-17 Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.

Country Status (38)

Country Link
US (2) US8927593B2 (es)
EP (2) EP3199531A1 (es)
JP (2) JP6367712B2 (es)
KR (1) KR101913800B1 (es)
CN (1) CN103732065B (es)
AR (1) AR087563A1 (es)
AU (1) AU2012299295B2 (es)
BR (1) BR112014002845A2 (es)
CA (1) CA2844086A1 (es)
CL (2) CL2014000393A1 (es)
CO (1) CO6862153A2 (es)
CR (1) CR20140078A (es)
CY (1) CY1118399T1 (es)
DK (1) DK2744332T3 (es)
DO (1) DOP2014000034A (es)
EA (1) EA032841B1 (es)
ES (1) ES2611731T3 (es)
HR (1) HRP20161743T1 (es)
HU (1) HUE030300T2 (es)
IL (1) IL230487B (es)
IN (1) IN2014CN00572A (es)
JO (1) JO3281B1 (es)
LT (1) LT2744332T (es)
MA (1) MA35443B1 (es)
ME (1) ME02588B (es)
MX (1) MX354676B (es)
PE (1) PE20141201A1 (es)
PH (1) PH12014500385A1 (es)
PL (1) PL2744332T3 (es)
PT (1) PT2744332T (es)
RS (1) RS55462B1 (es)
SG (1) SG10201606883QA (es)
SI (1) SI2744332T1 (es)
SM (2) SMT201700028T1 (es)
TW (1) TWI538915B (es)
UY (1) UY34274A (es)
WO (1) WO2013028371A1 (es)
ZA (1) ZA201401020B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101975233B1 (ko) * 2011-08-17 2019-05-07 글락소스미스클라인 엘엘씨 치료 방법
PH12014500385A1 (en) 2011-08-19 2020-06-22 Glaxo Group Ltd Benzofuran compounds for the treatment of hepatitis c virus infections
EA201790776A1 (ru) 2014-11-10 2017-11-30 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Комбинированные композиции длительного действия и способы лечения гепатита с
CR20170191A (es) * 2014-11-10 2017-09-29 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmacéuticas de acción prolongada para la hepatitis c
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
WO2018026656A1 (en) * 2016-08-01 2018-02-08 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
CN110621672A (zh) * 2017-03-02 2019-12-27 组装生物科学股份有限公司 环状磺酰胺化合物及其使用方法
CN111868063B (zh) * 2018-01-17 2023-08-01 葛兰素史克知识产权开发有限公司 PI4KIIIβ抑制剂
CA3155559A1 (en) * 2019-10-25 2021-04-29 Sachiko Koike Novel substituted condensed ring compound
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2001002424A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
EP2251344B2 (en) 2001-01-25 2024-04-24 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Formulation of boronic acid compounds
AU2003290584B2 (en) 2002-11-01 2009-07-16 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
WO2008051244A2 (en) 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis c virus
PL1988779T3 (pl) 2006-02-16 2015-10-30 Anacor Pharmaceuticals Inc Małe cząsteczki zawierające bor jako środki przeciwzapalne
WO2007131072A2 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
JP4827986B2 (ja) 2007-06-08 2011-11-30 マンカインド コーポレ−ション IRE−1αインヒビター
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
JP2011512341A (ja) 2008-02-14 2011-04-21 エフ.ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
EP2187893A4 (en) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
TW201138786A (en) 2010-02-19 2011-11-16 Glaxo Group Ltd Therapeutic compounds
AR080433A1 (es) 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201221131A (en) 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
KR101975233B1 (ko) * 2011-08-17 2019-05-07 글락소스미스클라인 엘엘씨 치료 방법
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
PH12014500385A1 (en) 2011-08-19 2020-06-22 Glaxo Group Ltd Benzofuran compounds for the treatment of hepatitis c virus infections

Also Published As

Publication number Publication date
HUE030300T2 (en) 2017-04-28
AU2012299295A1 (en) 2014-02-20
WO2013028371A1 (en) 2013-02-28
CN103732065B (zh) 2016-10-26
HRP20161743T1 (hr) 2017-02-24
US8927593B2 (en) 2015-01-06
CO6862153A2 (es) 2014-02-10
IL230487B (en) 2019-06-30
CN103732065A (zh) 2014-04-16
EP2744332B1 (en) 2016-10-26
US9682999B2 (en) 2017-06-20
PL2744332T3 (pl) 2017-03-31
MX2014001989A (es) 2014-02-27
PE20141201A1 (es) 2014-10-03
CY1118399T1 (el) 2017-06-28
EP3199531A1 (en) 2017-08-02
JO3281B1 (ar) 2018-09-16
SG10201606883QA (en) 2016-10-28
EP2744332A1 (en) 2014-06-25
CR20140078A (es) 2014-03-20
JP6367712B2 (ja) 2018-08-01
IL230487A0 (en) 2014-03-31
TW201321390A (zh) 2013-06-01
SI2744332T1 (sl) 2017-01-31
PT2744332T (pt) 2017-01-24
JP2017125010A (ja) 2017-07-20
AU2012299295B2 (en) 2016-03-31
US20130237501A1 (en) 2013-09-12
ME02588B (me) 2017-06-20
DOP2014000034A (es) 2014-06-01
IN2014CN00572A (es) 2015-04-03
LT2744332T (lt) 2017-01-10
RS55462B1 (sr) 2017-04-28
SMT201700028B (it) 2017-03-08
TWI538915B (zh) 2016-06-21
UY34274A (es) 2013-04-05
AR087563A1 (es) 2014-04-03
MX354676B (es) 2018-03-15
KR20140054287A (ko) 2014-05-08
ES2611731T3 (es) 2017-05-10
EP2744332A4 (en) 2015-01-14
US20150080343A1 (en) 2015-03-19
EA032841B1 (ru) 2019-07-31
ZA201401020B (en) 2020-11-25
CL2014000393A1 (es) 2014-08-01
CA2844086A1 (en) 2013-02-28
EA201490213A1 (ru) 2014-07-30
MA35443B1 (fr) 2014-09-01
DK2744332T3 (en) 2017-01-16
JP2014527529A (ja) 2014-10-16
SMT201700028T1 (it) 2017-03-08
BR112014002845A2 (pt) 2017-02-21
PH12014500385A1 (en) 2020-06-22
KR101913800B1 (ko) 2018-11-01

Similar Documents

Publication Publication Date Title
CL2017000293A1 (es) Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)
ECSP14004812A (es) Triazolopiridinas sustituidas
MX373711B (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CO6811860A2 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CL2016000381A1 (es) Compuestos antivirales
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
CR20140405A (es) Apoptosis señal reguladores del inhibidor de quinasa
MX2020011810A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CR20150629A (es) Compuestos químicos
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP13013011A (es) Triazolopiridinas
CR20130671A (es) Antagonistas de trpv4
CO6650348A2 (es) Triazolopiridinas sustituidas
CR20130054A (es) Procesos para preparar compuestos antivirales
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
AR095353A1 (es) Compuesto
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
DOP2016000232A (es) Compuestos químicos
AR102569A1 (es) Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende
AR086606A1 (es) Compuestos del complejo de fe(iii) para el tratamiento y profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro
AR101389A1 (es) Composición que contiene apomorfina y un catión de metal divalente